7780 — Daiken Biomedical Co Balance Sheet
0.000.00%
- TWD12.51bn
- TWD11.32bn
- TWD1.36bn
- 55
- 21
- 50
- 36
Annual balance sheet for Daiken Biomedical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | — |
Status: | Final | Final | Final |
Cash | |||
Cash and Equivalents | |||
Cash and Short Term Investments | 244 | 287 | 1,140 |
Net Total Accounts Receivable | |||
Net Total Receivables | 53.5 | 71.5 | 94.2 |
Total Inventory | |||
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 524 | 733 | 1,511 |
Net Property, Plant And Equipment | — | 0 | 3.28 |
Net Intangible Assets | |||
Other Long Term Assets | |||
Total Assets | 530 | 745 | 1,538 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Current Portion of Long Term Debt / Capital Leases | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 241 | 448 | 230 |
Long Term Debt | |||
Capital Lease Obligations | |||
Total Long Term Debt | |||
Total Debt | |||
Total Liabilities | 303 | 498 | 231 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Other Equity | |||
Total Equity | 227 | 247 | 1,307 |
Total Liabilities & Shareholders' Equity | 530 | 745 | 1,538 |
Total Common Shares Outstanding |